1. Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough in a phase 2b randomised controlled trial
- Author
-
Smith, Jacky, Kitt, Michael M, Morice, Alyn H, Birring, Surinder S, McGarvey, Lorcan P, Sher, Mandel R, Li, Yu-Ping, Wu, Wen-Chi, Xu, Zhi Jin, Muccino, David R, and Ford, Anthony P
- Abstract
Background: Gefapixant is a P2X3 receptor antagonist for treatment of refractory (RCC) and unexplained chronic cough (UCC). The aim of this study was to evaluate 12 weeks of gefapixant compared with placebo after 12 weeks of treatment for RCC/UCC. Methods: We conducted a 12-week, Phase 2b, randomized, double-blind, placebo-controlled study in RCC or UCC (>1 year) patients (no radiographic chest abnormality; ≥40 mm on the Cough Severity Visual Analog Scale [VAS]) recruited from 44 secondary/tertiary care sites in UK and US (clinicaltrials.gov: NCT02612610, status closed). Patients were randomized to placebo or gefapixant (7·5 mg twice daily [BID], 20 mg BID, or 50 mg BID). The primary endpoint was placebo-adjusted change from baseline in Awake Cough Frequency (coughs/hour) after 12 weeks analysed by intention-to-treat analysis. Adverse events (AE) were monitored and safety was evaluated in all patients receiving ≥1 dose of study drug. Findings: Between December 2015 and July 2016 253 patients were randomized to placebo (n=63), gefapixant 7·5 mg (n=64), 20 mg (n=63), or 50 mg (n=63). Mean (SD) age was 60 (10·0) years and 76% of patients were women. At 12 weeks, Geometric Mean Awake Cough Frequency was 18·2, 14·5, 12·0, 11·3 coughs/hr with placebo and gefapixant 7·5 mg, 20 mg, and 50 mg, respectively; percent change vs. placebo (95% CI) was -37% (-53·3,-14·9) with gefapixant 50 mg (p=0·003), -22·2% (-42,4·3) with 20 mg (p=0·093), and -22·0% (-41·8,4·6) with 7·5 mg (p=0·097). Dysgeusia was the most common AE, occurring in 5%, 10%, 33%, and 48% of placebo and gefapixant 7·5-mg, 20-mg, and 50-mg patients, respectively. Interpretation: Targeting P2X3 with gefapixant at a dose of 50 mg BID significantly reduces cough frequency in patients with RCC and UCC after 12 weeks of treatment compared with placebo. Gefapixant was generally well tolerated with dysgeusia being the most frequent AE.
- Published
- 2020